Open-label, single ascending dose and multiple single dose study in healthy volunteers to
evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single
ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study
consists of a single dose given daily for 6 consecutive days.
Phase:
Phase 1
Details
Lead Sponsor:
Humanetics Corporation
Collaborators:
Joint Warfighter Medical Research Program United States Department of Defense